HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant

@article{Simonich2016HIV1NA,
  title={HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant},
  author={Cassandra A. Simonich and K. Williams and H. Verkerke and J. A. Williams and R. Nduati and K. Lee and J. Overbaugh},
  journal={Cell},
  year={2016},
  volume={166},
  pages={77-87}
}
  • Cassandra A. Simonich, K. Williams, +4 authors J. Overbaugh
  • Published 2016
  • Medicine, Biology
  • Cell
  • HIV-1 broadly neutralizing antibodies (bnAbs) develop in a subset of infected adults and exhibit high levels of somatic hypermutation (SHM) due to years of affinity maturation. There is no precedent for eliciting highly mutated antibodies by vaccination, nor is it practical to wait years for a desired response. Infants develop broad responses early, which may suggest a more direct path to generating bnAbs. Here, we isolated ten neutralizing antibodies (nAbs) contributing to plasma breadth of an… CONTINUE READING
    Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
    24
    CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals from HIV-1 Subtype C Infected Indian Children
    7

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 66 REFERENCES
    Early development of broad neutralizing antibodies in HIV-1 infected infants
    107
    Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1
    59
    Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies †
    84
    HIV-1 neutralizing antibodies induced by native-like envelope trimers
    355
    Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
    537
    HIV-1 gp120 Vaccine Induces Affinity Maturation in both New and Persistent Antibody Clonal Lineages
    80
    Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization
    379
    Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen
    229